LenioBio Secures Significant EU4Health Funding to Advance Protein-Based Medicine Production
[City, State] – July 23, 2025 – LenioBio, a pioneering company in the field of biotechnology, announced today that it has been awarded EUR 3.7 million in funding from the EU4Health program. This substantial investment will be instrumental in the further development of LenioBio’s innovative ALiCE® platform, designed to revolutionize the cost-effective and rapid production of protein-based medicines.
The EU4Health program, a key initiative by the European Union, aims to strengthen healthcare systems and improve the availability of essential medicines across member states. LenioBio’s successful bid for this funding underscores the significant potential of their ALiCE® technology to address critical needs within the pharmaceutical industry, particularly in making advanced protein-based therapeutics more accessible and affordable.
The ALiCE® (Advanced Lytic Cell Expression) platform is a proprietary cell-free protein expression system. Unlike traditional methods that rely on living cells, ALiCE® utilizes an optimized cell lysate to produce therapeutic proteins. This innovative approach promises several key advantages, including significantly faster production timelines, reduced manufacturing costs, and enhanced product quality and purity. These benefits are particularly crucial for the development and scaling of complex protein-based medicines, such as antibodies, enzymes, and other biologics, which are vital for treating a wide range of diseases.
With this substantial funding, LenioBio plans to accelerate the optimization and industrialization of the ALiCE® platform. The company intends to focus on enhancing its production capacity, further streamlining the manufacturing process, and expanding its application to a broader spectrum of protein targets. This will not only solidify LenioBio’s position as a leader in next-generation biomanufacturing but also contribute to greater European self-sufficiency in the production of life-saving medicines.
“We are incredibly honored and excited to receive this significant funding from the EU4Health program,” said [Name and Title of a LenioBio Representative – e.g., Dr. Anya Sharma, CEO of LenioBio]. “This award is a testament to the transformative potential of our ALiCE® technology. It will empower us to accelerate our efforts in making critical protein-based medicines more accessible and affordable for patients across Europe and beyond. We are confident that ALiCE® will play a pivotal role in the future of biopharmaceutical manufacturing, enabling faster innovation and improved patient outcomes.”
The development of cost-effective and rapid production methods for protein-based medicines is a critical global health priority. By leveraging its advanced ALiCE® technology, LenioBio is poised to make a significant impact, potentially leading to reduced treatment costs and improved availability of essential therapies for various medical conditions. This EU4Health funding represents a crucial step forward in realizing that vision.
AI has delivered the news.
The answer to the following question is obtained from Google Gemini.
PR Newswire Healthring published ‘LenioBio secures EUR 3.7M of EU4Health funding to develop ALiCE® for cost-effective and rapid production of protein-based medicines’ at 2025-07-23 07:00. Please write a detailed article about this news in a polite tone with relevant information. Please reply in English with the article only.